These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 26365905)

  • 1. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Dholariya S; Dutta S; Singh R; Parchwani D; Sonagra A; Kaliya M
    Expert Opin Pharmacother; 2023; 24(18):2187-2198. PubMed ID: 37817422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
    Musso G; Gambino R; Cassader M; Pagano G
    Ann Med; 2012 Jun; 44(4):375-93. PubMed ID: 21495788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
    Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A
    Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis.
    Zhang L; Zhang M; Lv Q; Tong N
    Diabetes Res Clin Pract; 2018 Jun; 140():295-303. PubMed ID: 29649541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
    J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tian B; Deng Y; Cai Y; Han M; Xu G
    Nephrol Dial Transplant; 2022 Mar; 37(4):720-729. PubMed ID: 33605424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Storgaard H; Gluud LL; Bennett C; Grøndahl MF; Christensen MB; Knop FK; Vilsbøll T
    PLoS One; 2016; 11(11):e0166125. PubMed ID: 27835680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Vasilakou D; Karagiannis T; Athanasiadou E; Mainou M; Liakos A; Bekiari E; Sarigianni M; Matthews DR; Tsapas A
    Ann Intern Med; 2013 Aug; 159(4):262-74. PubMed ID: 24026259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
    Mazidi M; Rezaie P; Gao HK; Kengne AP
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhang S; Qi Z; Wang Y; Song D; Zhu D
    Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.